Eli Lilly’s (NYSE: LLY) Alzheimer’s drug Kisunla gets positive news

Eli Lilly (NYSE: LLY) Alzheimer’s treatment Kisunla (donanemab) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending the drug for the treatment of early symptomatic Alzheimer’s disease.

The European Commission is expected to make a final regulatory decision on donanemab in the coming months, following this recommendation.

The CHMP based its positive opinion primarily on data from two clinical trials: TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6. These trials provided the evidence that supported the committee’s recommendation for approval.

If approved by the European Commission, Kisunla would become available as a treatment option for patients with early symptomatic Alzheimer’s disease across European Union member states.